US · CTXR · BIOTECHNOLOGY
Citius Pharmaceuticals, Inc. (CTXR) intrinsic value and stock valuation
$0.51as of 2026-11-21 · Mkt cap 7.62M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Citius Pharmaceuticals, Inc. DCF and intrinsic value
InvestorsCraft values CTXR with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CTXR’s statements →
Citius Pharmaceuticals, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating income | -$-38.53M | -$-42M | -$-36.73M | -$-33.32M | -$-23.53M |
| Net income | -$-37.43M | -$-39.14M | -$-32.54M | -$-33.64M | -$-23.13M |
| EPSd | -$-3.38M | -$-3.38M | -$-3.22M | -$-3.45M | -$-3.19M |
| Operating cash flow | -$-26.55M | -$-28.2M | -$-29.06M | -$-28.36M | -$-24.25M |
| Capital expenditure | $0.00 | $0.00 | $0.00 | $0.00 | -$-40.01M |
| Free cash flow | -$-26.55M | -$-28.2M | -$-29.06M | -$-28.36M | -$-64.26M |
| Total assets | $130.9M | $116.7M | $103.6M | $114M | $142.4M |
| Total debt | $1.81M | $260K | $480K | $680K | $860K |
| Net debt | -$-2.44M | -$-2.99M | -$-26M | -$-41.03M | -$-69.22M |
| Total equity | $77.5M | $74.1M | $91.4M | $103.4M | $132.8M |
| Cash and short-term investments | $4.25M | $3.25M | $26.5M | $41.7M | $70.1M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $210K | $210K | $190K | $180K | $160K |
| Gross profit | -$-210K | -$-210K | -$-190K | -$-180K | -$-160K |
| Research and development expenses | $9.16M | $11.9M | $14.8M | $17.7M | $12.2M |
| Selling, general and administrative expenses | $18.5M | $18.3M | $21.9M | $15.7M | $11.3M |
| Other expenses | $10.6M | $11.8M | $0.00 | $0.00 | $0.00 |
| Operating expenses | $38.3M | $42M | $36.7M | $33.3M | $23.5M |
| Cost and expenses | $38.5M | $42M | $36.7M | $33.3M | $23.5M |
| Interest income | $110K | $760K | $1.18M | $250K | $260K |
| Interest expense | $270K | $0.00 | $0.00 | $250K | $10K |
| Depreciation and amortization | $210K | $210K | $190K | $180K | $160K |
| Ebitda | -$-38.2M | -$-38.64M | -$-31.77M | -$-32.88M | -$-22.88M |
| Operating income | -$-38.53M | -$-42M | -$-36.73M | -$-33.32M | -$-23.53M |
| Total other income/expenses, net | -$-160K | $3.15M | $4.77M | $250K | $480K |
| Income before tax | -$-38.68M | -$-38.85M | -$-31.97M | -$-33.06M | -$-23.05M |
| Income tax expense | $1.06M | $580K | $580K | $580K | $0.00 |
| Net income | -$-37.43M | -$-39.14M | -$-32.54M | -$-33.64M | -$-23.13M |
| Weighted average shares outstanding | $11.1M | $11.6M | $9.74M | $9.74M | $7.24M |
| Weighted average diluted shares outstanding | $11.1M | $11.6M | $10.1M | $9.74M | $7.24M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $4.25M | $3.25M | $26.5M | $41.7M | $70.1M |
| Net receivables | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $22.3M | $8.27M | $0.00 | $0.00 | $0.00 |
| Total current assets | $27.9M | $14.2M | $34.4M | $44.6M | $72.8M |
| Property, plant and equipment, net | $820K | $250K | $460K | $650K | $830K |
| Goodwill and intangible assets | $102.2M | $102.2M | $68.8M | $68.8M | $68.8M |
| Long-term investments | $0.00 | $0.00 | $44.9M | $0.00 | $29.2M |
| Total non-current assets | $103M | $102.4M | $69.2M | $69.4M | $69.6M |
| Total assets | $130.9M | $116.7M | $103.6M | $114M | $142.4M |
| Accounts payable | $13.7M | $4.93M | $2.93M | $1.17M | $1.28M |
| Short-term debt | $1.09M | $480K | $440K | $390K | $350K |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $44.9M | $35.8M | $5.78M | $4.53M | $3.98M |
| Long-term debt | $720K | $20K | $260K | $480K | $680K |
| Deferred revenue, non-current | $0.00 | $0.00 | -$-10K | -$-10K | -$0.00 |
| Total non-current liabilities | $8.5M | $6.74M | $6.4M | $6.04M | $5.66M |
| Capital lease obligations | $810K | $260K | $480K | $680K | $860K |
| Total liabilities | $53.4M | $42.6M | $12.2M | $10.6M | $9.65M |
| Common stock | $20K | $10K | $160K | $150K | $150K |
| Retained earnings | -$-238.8M | -$-201.37M | -$-162.23M | -$-129.69M | -$-96.05M |
| Accumulated other comprehensive income (loss) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total equity | $77.5M | $74.1M | $91.4M | $103.4M | $132.8M |
| Total investments | $0.00 | $0.00 | $44.9M | $0.00 | $29.2M |
| Total debt | $1.81M | $260K | $480K | $680K | $860K |
| Net debt | -$-2.44M | -$-2.99M | -$-26M | -$-41.03M | -$-69.22M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-39.74M | -$-39.43M | -$-32.54M | -$-33.64M | -$-23.05M |
| Depreciation and amortization | $210K | $210K | $190K | $180K | $160K |
| Stock-based compensation | $10.8M | $11.8M | $6.62M | $3.91M | $1.45M |
| Change in working capital | $1.05M | -$-1.69M | -$-4.01M | $240K | -$-2.72M |
| Accounts receivable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | -$-12.65M | -$-2.13M | $0.00 | $0.00 | $0.00 |
| Accounts payable | $8.77M | $2M | $1.76M | -$-110K | -$-580K |
| Net cash provided by operating activities | -$-26.55M | -$-28.2M | -$-29.06M | -$-28.36M | -$-24.25M |
| Investments in property, plant and equipment | -$-5.75M | $0.00 | $0.00 | $0.00 | -$-40.01M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-5.75M | -$-5M | $0.00 | $0.00 | -$-40.01M |
| Common stock issued | $32.3M | $13.8M | $13.8M | $0.00 | $89.4M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $33.3M | $9.97M | $13.8M | $0.00 | $120.5M |
| Net change in cash | $1M | -$-23.23M | -$-15.23M | -$-28.36M | $56.2M |
| Cash at end of period | $4.25M | $3.25M | $26.5M | $41.7M | $70.1M |
| Operating cash flow | -$-26.55M | -$-28.2M | -$-29.06M | -$-28.36M | -$-24.25M |
| Capital expenditure | $0.00 | $0.00 | $0.00 | $0.00 | -$-40.01M |
| Free cash flow | -$-26.55M | -$-28.2M | -$-29.06M | -$-28.36M | -$-64.26M |
Line items
Line items
Line items
About Citius Pharmaceuticals, Inc.
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
- CEO
- Leonard L. Mazur
- Employees
- 23
- Beta
- 0.98
Explore
Frequently asked questions
What is the intrinsic value of Citius Pharmaceuticals, Inc. (CTXR)?
InvestorsCraft does not currently publish an intrinsic value for CTXR. How the IC value is calculated.
Is CTXR undervalued?
InvestorsCraft does not publish an undervaluation signal for CTXR at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.